- Home
- EXP vs JAZZ Comparison
EXP vs JAZZ Comparison
Compare EXP & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXP
- JAZZ
- Stock Information
- Founded
- EXP 1963
- JAZZ 2003
- Country
- EXP United States
- JAZZ Ireland
- Employees
- EXP N/A
- JAZZ N/A
- Industry
- EXP Building Materials
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- EXP Industrials
- JAZZ Health Care
- Exchange
- EXP Nasdaq
- JAZZ Nasdaq
- Market Cap
- EXP 6.4B
- JAZZ 6.7B
- IPO Year
- EXP 1994
- JAZZ 2007
- Fundamental
- Price
- EXP $223.38
- JAZZ $110.27
- Analyst Decision
- EXP Buy
- JAZZ Strong Buy
- Analyst Count
- EXP 9
- JAZZ 12
- Target Price
- EXP $262.78
- JAZZ $183.08
- AVG Volume (30 Days)
- EXP 437.3K
- JAZZ 651.1K
- Earning Date
- EXP 07-29-2025
- JAZZ 07-30-2025
- Dividend Yield
- EXP 0.45%
- JAZZ N/A
- EPS Growth
- EXP 1.18
- JAZZ 49.21
- EPS
- EXP 13.77
- JAZZ 7.51
- Revenue
- EXP $2,260,508,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- EXP $2.63
- JAZZ $6.05
- Revenue Next Year
- EXP $5.43
- JAZZ $4.68
- P/E Ratio
- EXP $16.21
- JAZZ $14.72
- Revenue Growth
- EXP 0.05
- JAZZ 5.76
- 52 Week Low
- EXP $191.91
- JAZZ $95.49
- 52 Week High
- EXP $321.93
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- EXP 63.17
- JAZZ 52.75
- Support Level
- EXP $211.38
- JAZZ $109.27
- Resistance Level
- EXP $228.82
- JAZZ $112.70
- Average True Range (ATR)
- EXP 5.84
- JAZZ 2.72
- MACD
- EXP 3.01
- JAZZ 0.42
- Stochastic Oscillator
- EXP 83.53
- JAZZ 67.81
About EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.